Biotech Values

[DewDiligence]

Notes from ENTA’s WF webcast:

• ABT-493 + (ABBV’s) ABT-530: Monotherapy cohorts in HCV patients are done; phase-2 combination study in HCV patients will start this summer.

• EDP-239: Monotherapy cohorts in HCV patients are almost done; phase-2 DDI trial with NVS’ alisporvir* in healthy volunteers starts 2Q14 (i.e. very soon); phase-2b trial of EDP-239 + alisporvir in HCV patients will start at conclusion of DDI trial, at which point ENTA will earn a $15M milestone payment from NVS.

*Cyclophilin inhibitor f/k/a DEB 025.